Core Insights - Alibaba Health and Shengxiang Bio have signed a strategic cooperation agreement focusing on respiratory infectious diseases, aiming to enhance home testing capabilities and improve the "home flash testing" service experience on Taobao [1][3] Group 1: Strategic Cooperation - The partnership will leverage Shengxiang Bio's expertise in respiratory pathogen detection to provide advanced home testing services, ensuring accuracy and stability in test results [3] - The initial project will be the "12-pathogen respiratory virus and bacteria test," which covers 12 common respiratory pathogens, addressing diverse testing needs during flu season [2][3] Group 2: Market Trends - The home testing industry is experiencing rapid growth, driven by demand, policy support, and technological advancements, with major internet platforms like Alibaba, JD.com, and Meituan entering the market [4][5] - The home testing market in China is projected to grow from 120 billion yuan to 280 billion yuan between 2025 and 2030, with a compound annual growth rate of 18.5% [5] Group 3: Industry Dynamics - The integration of home testing services with online medical consultations is expected to enhance patient engagement and streamline the transition from diagnosis to medication [6] - Meituan and JD Health have also launched similar home testing services, expanding their offerings to include various health assessments and increasing their operational capacity in response to rising demand [4][7]

Core Insights - Alibaba Health reported a total revenue of 16.697 billion RMB for the six months ending September 30, 2025, representing a year-on-year growth of 17.0% [1] - The net profit reached 1.266 billion RMB, showing a significant increase of 64.7% compared to the previous year, with a net profit margin rising from 5.4% to 7.6% [1] - Adjusted net profit was 1.356 billion RMB, reflecting a year-on-year growth of 38.7% [1] Group 1: Business Performance - The Tmall Health platform maintained continuous growth in annual active consumers, with a stable increase in gross merchandise volume over the past six months [1] - The number of online products increased by over 24% to more than 97 million stock-keeping units, while the number of service merchants grew by over 39% to exceed 56,000 [1] - Self-operated business revenue reached 14.380 billion RMB, marking an 18.6% year-on-year increase, with prescription drugs and original research drugs categories experiencing rapid growth [1][2] Group 2: Strategic Initiatives - The company capitalized on supply-side structural optimization opportunities in the healthcare product categories, continuously enhancing the operational efficiency of its self-operated business [2] - Alibaba Health is deepening partnerships with pharmaceutical companies, actively introducing leading brands, and expanding collaboration channels to further enhance user perception [2] - The company is upgrading its healthcare service experience, providing integrated online and offline medical services across multiple platforms, including traditional Chinese medicine, health checks, diagnostics, consultations, appointments, vaccinations, dental care, psychological services, vision care, and nursing [2]

Core Insights - Alibaba Health reported a revenue of RMB 16.697 billion for the six months ending September 30, 2025, representing a year-on-year growth of 17% [2] - The company achieved a gross profit of RMB 4.184 billion, up 18.4% year-on-year, and a net profit of RMB 1.266 billion, which increased by 64.7% [2] - Adjusted net profit reached RMB 1.356 billion, reflecting a year-on-year growth of 38.7% [2] Financial Performance - Revenue for the self-operated pharmacy business was RMB 14.38 billion, marking an 18.6% increase year-on-year [2] - The number of active users and annual ARPU for the self-operated business continued to grow, with SKUs increasing by 98.8% to 1.61 million [2] Strategic Initiatives - Alibaba Health is focusing on deepening its investment in the medical AI sector and enhancing its strategic layout in the toB medical verticals [2][4] - The company has partnered with leading pharmaceutical brands to provide comprehensive services from drug launch to patient education and online consultations [3] - The integration of online and offline healthcare services has been emphasized, with over 250,000 healthcare professionals providing online consultation services [3] AI and Technology Development - Alibaba Health is increasing resource investment in medical AI applications to improve user experience and search conversion efficiency [4] - The company aims to explore applications in serious medical fields, enhancing the evidence-based capabilities of its models in clinical decision-making and research [4]

Core Insights - Alibaba Health reported a revenue of 16.697 billion yuan for the first half of the fiscal year 2026, representing a year-on-year growth of 17% [1] - The company achieved a gross profit of 4.184 billion yuan, up 18.4% year-on-year, and a net profit of 1.266 billion yuan, which is a significant increase of 64.7% [1] - Adjusted net profit reached 1.356 billion yuan, reflecting a growth of 38.7% [1] - The company is committed to investing in the medical AI sector and enhancing its strategic layout in the B2B medical vertical [1] Business Performance - Alibaba Health is the largest online B2C healthcare product retail platform in China, with over 56,000 active merchants and an increase of over 97 million SKUs [1] - The platform's annual active user count and annualized ARPU continue to grow, with GMV showing stable high-quality growth [1] - The self-operated pharmacy business generated revenue of 14.38 billion yuan, marking an 18.6% increase, with a 98.8% year-on-year growth in SKUs to 1.61 million [1] Strategic Collaborations - Alibaba Health has deepened partnerships with major pharmaceutical companies, launching dozens of new specialty drugs and providing comprehensive services from drug listing to patient education and delivery [2] - Collaborations with leading firms such as Eli Lilly, AstraZeneca, and Pfizer focus on digital health services, expanding the outpatient market for pharmaceutical partners [2] Integrated Health Services - The company offers integrated online and offline healthcare services, with over 250,000 licensed healthcare professionals providing online consultation services [2] - Alibaba Health's internet hospital continues to serve chronic disease patients, with user numbers and ARPU showing consistent growth [2] Traditional Chinese Medicine (TCM) Services - The TCM service segment is experiencing stable growth, with the establishment of a self-operated TCM dispensing center network across several provinces [3] - The company has over 150,000 registered TCM practitioners, enhancing its medical service network [3] Digital Infrastructure and AI Development - The "Code on Trust" platform provides free traceability services to 560,000 pharmaceutical enterprises, expanding its reach into medical devices and traditional Chinese medicine [3] - Alibaba Health collaborates with over 900 leading pharmaceutical companies to provide data analysis services [3] - The company is increasing investments in medical AI, aiming to improve user experience and explore applications in serious medical fields [3]

Core Viewpoint - Alibaba Health reported a strong financial performance for the first half of the fiscal year 2026, with significant growth in revenue, gross profit, and net profit, while continuing to invest in the medical AI sector to enhance its strategic positioning in the B2B healthcare market [1] Financial Performance - Revenue reached RMB 16.697 billion, representing a year-on-year increase of 17% [1] - Gross profit amounted to RMB 4.184 billion, with a year-on-year growth of 18.4% [1] - Net profit was RMB 1.266 billion, showing a substantial year-on-year increase of 64.7% [1] - Adjusted net profit stood at RMB 1.356 billion, reflecting a year-on-year growth of 38.7% [1] Business Growth and Strategy - The company maintains a robust and high-quality growth trajectory, focusing on enhancing product offerings and user experience to meet increasing health demands [1] - As the largest online B2C healthcare product retail platform in China, Alibaba Health serves over 56,000 merchants on the Tmall Health platform, with SKU growth exceeding 97 million [1] - The platform's GMV has achieved stable year-on-year growth, supported by an increase in active annual users and annual ARPU [1] Operational Efficiency - Alibaba Health's self-operated pharmacy business has significantly improved operational efficiency, leading to enhanced profitability [1] - Business revenue for the self-operated segment reached RMB 14.38 billion, marking an 18.6% year-on-year increase [1] - Active annual users and member ARPU continue to grow, with SKU count increasing by 98.8% to 1.61 million [1]

同时，集团持续投入在医疗AI垂类领域。作为阿里巴巴集团在医疗健康领域的旗舰平台，集团不断深 化在to B的医疗垂类领域的AI应用和工具的佈局，探索满足医疗行业及医生不断增长的AI需求，加速医 疗AI领域的深耕与突破，推动业务高质量发展。 阿里健康(00241)发布截至2025年9月30日止六个月的中期业绩，集团业务保持高质量稳健增长，总收入 为166.97亿元人民币，同比增长17.0%。净利润额为12.66亿元人民币，同比增长64.7%。净利润率由 5.4%增长至7.6%。调整后净利润额为13.56亿元人民币，同比增长38.7%。 报告期内，阿里健康自营业务抓住医疗健康品等类目的供给侧结构性优化的机遇，持续提升自营业务的 运营效率，业务收入达143.8亿元人民币，同比增长18.6%。同时集团持续深化药企合作，积极引入头部 品牌，拓展合作渠道，进一步提升用户心智。自营业务的年度活跃用户数与会员ARPU持续增长。 截至2025年9月30日，公司运营的天猫健康平台拥有年化活跃消费者(过往于十二个月内在天猫健康平台 实际购买过一次或以上商品的消费者)保持持续增长，天猫健康平台商品交易总额(GMV)在过去六个月 中实现 ...

Core Insights - Alibaba Health reported a revenue of RMB 16.697 billion for the six months ending September 30, 2025, representing a year-on-year growth of 17% [1] - Gross profit reached RMB 4.184 billion, up 18.4% year-on-year, while net profit surged by 64.7% to RMB 1.266 billion [1] - Adjusted net profit was RMB 1.356 billion, reflecting a year-on-year increase of 38.7% [1] Revenue and User Growth - The number of merchants on the Tmall Health platform exceeded 56,000, with SKUs increasing by over 97 million [1] - Annual active user numbers and annualized ARPU continued to grow, with platform GMV achieving stable year-on-year growth [1] - The self-operated business revenue reached RMB 14.38 billion, marking an 18.6% increase year-on-year [1] Strategic Collaborations - Alibaba Health partnered with leading pharmaceutical companies such as Eli Lilly, AstraZeneca, and Pfizer to launch dozens of new specialty drugs [2] - The company is expanding digital health services through strategic collaborations in online retail, category expansion, and disease education [2] - Over 250,000 healthcare professionals, including licensed physicians and pharmacists, are now providing online health consultation services, an increase of over 20,000 from the previous year [2]

Core Insights - Alibaba Health (00241) reported a total revenue of 16.697 billion RMB for the six months ending September 30, 2025, representing a year-on-year growth of 17.0% [1] - The net profit reached 1.266 billion RMB, showing a significant increase of 64.7%, with the net profit margin rising from 5.4% to 7.6% [1] - Adjusted net profit was 1.356 billion RMB, reflecting a year-on-year growth of 38.7% [1] Revenue and Profitability - The company's self-operated business generated revenue of 14.38 billion RMB, marking an 18.6% year-on-year increase [1] - The annual active user count and average revenue per user (ARPU) for the self-operated business continued to grow [1] Platform Performance - The Tmall Health platform maintained a steady increase in annual active consumers, with the gross merchandise volume (GMV) showing high-quality stable growth over the past six months [1] - The company is enhancing operational efficiency in its self-operated business by seizing opportunities in the supply-side structural optimization of healthcare products [1] AI Investment - The company is continuously investing in the medical AI sector, focusing on deepening its AI applications and tools in the B2B medical vertical [2] - This initiative aims to meet the growing AI demands of the healthcare industry and physicians, promoting high-quality business development [2]

董事会预期截至2027年3月31日止两个财政年度的营销推广服务之原有年度上限将不足以满足集团的业 务需要。因此，于2025年11月26日，董事会建议按照上市规则第14A章的规定修订截至2027年3月31日 止两个财政年度的营销推广服务之原有年度上限。 格隆汇11月26日丨阿里健康(00241.HK)公告，内容有关（其中包括）公司与阿里妈妈就提供营销推广服 务而订立的2025年至2027年营销推广服务框架协议，为期三(3)年，自2024年4月1日起至2027年3月31日 止，除非根据其条款另行终止。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） （股份代號：00241） 持續關連交易 — 於本公告日期，阿里巴巴控股為本公司的最終控股股東。由於阿里巴巴控股直接 或間接控制阿里媽媽公司或為其阿里媽媽公司的最終股東，阿里媽媽公司成員公 司為阿里巴巴控股的聯繫人，因此為本公司關連人士。故根據上市規則，2025年 至2027年營銷推廣服務框架協議項下擬進行交易構成本公司持續關連交易。 根據上市規則第14A.54(1)條，本公司將須於營銷推廣服務之原有年度上限超額 之前重新遵守上市規則第14A章適用於相關持續關連交易的規定。由於參考2025 年至2027年營銷推廣服務框架協議項下經修訂年度上限計算的一項或多項適用百 分比率超過5%，故修訂營銷推廣服務之原有年度上限須遵守上市規則第14A章 項下的申報、公告、年 ...